Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Garcia Del Blanco B, Otaegui I, Rodriguez-Palomares JF, Bayes-Genis A, Fernandez-Nofrerias E, Vilalta Del Olmo V, Carrillo X, Ibanez B, Worner F, Casanova J, Pueo E, Gonzalez-Juanatey JR, Lopez-Pais J, Bardaji A, Bonet G, Fuertes M, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Barba I, Gomez-Talavera S, Marti G, Serra B, Bellera N, Ojeda-Ramos M, Cuellar H, Valente F, Carmona MA, Miro-Casas E, Marsal JR, Sambola A, Lidon RM, Baneras J, Elizaga J, Padilla F, Barrabes JA, Hausenloy DJ, Ferreira-Gonzalez I, Garcia-Dorado D. Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI). Basic Res Cardiol. 2021 Jan 25;116(1):4. doi: 10.1007/s00395-021-00842-2

Sharp L, McDevitt J, Brown C, Carsin AE, Comber H. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: results from a population-based analysis of 10,794 cases. Cancer. 2017 Jul 1;123(13):2543-50. doi: 10.1002/cncr.30583

Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014 Jun 15;120(12):1830-7. doi: 10.1002/cncr.28659

Martin P, Byrtek M, Dawson K, Ziemiecki RM, Friedberg JW, Cerhan JR, Flowers CR, Link BK. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Cancer. 2013 Dec 1;119(23):4129-36. doi: 10.1002/cncr.28350

Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci J-F, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 Mar 15;119(10):1908-15.